Back to Directory

Katie McCarthy

Email

kmccarthy@fhi360.org

Phone

(919) 321-3326

Institution

FHI 360

Title

Clinical Research Manager

Address

FHI 360
359 Blackwell St.
Suite 200
Durham, NC 27701
United States of America

Request an Update

Affiliated Studies

IMPAACT 2051: Phase II Study of the Pharmacokinetics, Safety, Tolerability, and Anti-Mycobacterial Activity of Pretomanid with Bedaquiline, Linezolid, with or without Moxifloxacin (BPaL/M) in Children with Rifampicin-Resistant Tuberculosis

DAIDS Number

39258

Research Area

Tuberculosis

Study Status

In Development

IMPAACT 2041: Phase I/II Study of the Pharmacokinetics and Safety of Glecaprevir/Pibrentasvir Initiated in Pregnancy in Women with Hepatitis C with and without HIV

DAIDS Number

39052

Research Area

Therapeutics

Study Status

Enrolling

IMPAACT 2034: Phase 1 Study of the Pharmacokinetics, Safety, and Acceptability of a Single Dose of Pretomanid Added to an Optimized Background Regimen in Children with Rifampicin-Resistant Tuberculosis

DAIDS Number

38754

Research Area

Tuberculosis

Study Status

Closed to Follow Up

1077HS: HAART Standard Version of the PROMISE Study (Maternal & Infant Survival)

DAIDS Number

10779

Research Area

Therapeutics

Study Status

Concluded

P1104s: Longitudinal Developmental and Neuropsychological Assessments of HIV-Infected Participants of P1060 and HIV-Uninfected Controls

DAIDS Number

11878

Research Area

Brain and Mental Health

Study Status

Participants Off Study and Primary Analysis Completed

Show All